

Volume 754
May 31, 1995

**COMBINED VACCINES AND
SIMULTANEOUS ADMINISTRATION
CURRENT ISSUES AND PERSPECTIVES^a**

Editors

JIM C. WILLIAMS, KAREN L. GOLDENTHAL, DRUSILLA L. BURNS,
and BENJAMIN P. LEWIS, JR.

Workshop Co-chairs

DRUSILLA L. BURNS and JIM C. WILLIAMS

Workshop Program Committee

DRUSILLA L. BURNS, JOY A. CAVAGNARO, ELAINE C. ESBER, KAREN L. GOLDENTHAL,
M. CAROLYN HARDEGREE, BENJAMIN P. LEWIS, JR., and JIM C. WILLIAMS

CONTENTS

Overview—Combination Vaccines and Simultaneous Administration:
Past, Present, and Future. *By* KAREN L. GOLDENTHAL,
DRUSILLA L. BURNS, LORIS D. MCVITTIE, BENJAMIN P. LEWIS, JR.,
and JIM C. WILLIAMS xi

**Part I. The Interface between Vaccine Initiatives, New Technologies,
and Vaccine Development**

ELAINE C. ESBER and M. TERESA AGUADO, *Co-chairs*

Combined and Simultaneously Administered Vaccines: A Brief History.
By PAUL D. PARKMAN 1

FDA Perspective on Regulatory Issues in Vaccine Development.
By BASCOM F. ANTHONY 10

Strategies for Developing Combination Vaccines. *By* RONALD J. SALDARINI . . . 17

Manufacturing Issues for Multivalent Vaccines. *By* ARTHUR Y. ELLIOTT 23

Combination Vaccines: Regulatory Issues. *By* D. K. MCCLINTOCK 27

^a This volume is the result of a conference entitled Combined Vaccines and Simultaneous Administration: Current Issues and Perspectives, which was sponsored by the Center for Biologics Evaluation and Research, United States Food and Drug Administration; the National Vaccine Program Office; the National Institute of Allergy and Infectious Diseases, the National Institutes of Health; the Centers for Disease Control and Prevention; and the World Health Organization. The conference was held on July 28–30, 1993 in Bethesda, Maryland.

Part II. Advances in the Development of Conjugate and Combination Vaccines

CLAIRE V. BROOME and GEOFFREY SCHILD, *Co-chairs*

| | |
|---|-----|
| Potential Alterations in Immunogenicity by Combining or Simultaneously Administering Vaccine Components. <i>By</i> RICHARD A. INSEL | 35 |
| Determinant Flanking Regions and the Design of Appropriate Vaccines. <i>By</i> LUIS SOARES, HONGKUI DENG, IQBAL S. GREWAL, VIPIN KUMAR, ALEXANDER MILLER, KAMAL D. MOUDGIL, MARK PALMER, and ELI E. SERCARZ | 48 |
| Selection of Carrier and B Cell Protectope Sequences for Vaccines. <i>By</i> HOWARD M. ETLINGER | 57 |
| Prevention of Systemic Infections Caused by Group B Streptococcus and <i>Staphylococcus aureus</i> by Multivalent Polysaccharide-Protein Conjugate Vaccines. <i>By</i> JOHN B. ROBBINS, RACHEL SCHNEERSON, WILLIE F. VANN, DOLORES A. BRYLA, and ALI FATTOM | 68 |
| Definition and Clinical Assessment of Consistency Lots for Combination Vaccines. <i>By</i> BERNARD FRITZELL | 83 |
| Immune Responses to Pertussis Vaccines Concurrently Administered with Viral Vaccines. <i>By</i> SCOTT A. HALPERIN, BRIAN J. EASTWOOD, and JOANNE M. LANGLEY | 89 |
| Comparative Evaluation of Immunization with Live Attenuated and Inactivated Poliovirus Vaccines. <i>By</i> PEARAY L. OGRA | 97 |
| Combination Vaccines for Diphtheria, Tetanus, Pertussis, and <i>Haemophilus influenzae</i> Type b. <i>By</i> PETER R. PARADISO | 108 |

Part III. New Approaches in Design and Use of Vaccine Adjuvants

WILLIAM E. PAUL and JOY A. CAVAGNARO, *Co-chairs*

| | |
|---|-----|
| The Biochemistry and Cell Biology of Antigen Presentation by MHC Class I and Class II Molecules: Implications for Development of Combination Vaccines. <i>By</i> RONALD N. GERMAIN | 114 |
| Vaccine Strategies: Targeting Helper T Cell Responses. <i>By</i> BASIL GOLDING and DOROTHY E. SCOTT | 126 |
| The Role of sIgA+ B Cells in Oral Immunity. <i>By</i> ROLF O. EHRHARDT and WARREN STROBER | 138 |
| Liposomal Vaccines: Clinical Status and Immunological Presentation for Humoral and Cellular Immunity. <i>By</i> CARL R. ALVING | 143 |
| Immunologic Adjuvants for Modern Vaccine Formulations. <i>By</i> FREDERICK R. VOGEL | 153 |
| Designing Peptide Vaccines to Broaden Recognition and Enhance Potency. <i>By</i> JAY A. BERZOFSKY | 161 |
| Galactose Oxidation as a Potent Vaccine Adjuvant Strategy: Efficacy in Murine Models and in Protection against a Bovine Parasitic Infection. <i>By</i> JOHN RHODES, BIAO ZHENG, and CHRISTOPHER A. MORRISON | 169 |

Part IV. New Antigen Delivery Systems: Construction and Use

BARRY R. BLOOM and JOHN R. LA MONTAGNE, *Co-chairs*

| | |
|--|-----|
| The Hepatitis Nucleocapsid as a Vaccine Carrier Moiety. <i>By</i> D. R. MILICH, D. L. PETERSON, J. ZHENG, J. L. HUGHES, R. WIRTZ, and F. SCHÖDEL . . . | 187 |
| Yeast Retrotransposon Particles as Antigen Delivery Systems. <i>By</i> ALAN J. KINGSMAN, NIGEL R. BURNS, GUY T. LAYTON, and SALLY E. ADAMS | 202 |
| Progress on Development of the Live BCG Recombinant Vaccine Vehicle for Combined Vaccine Delivery. <i>By</i> MARK S. HANSON, CLAUDIA VIGIL LAPCEVICH, and SHIRLEY L. HAUN | 214 |
| Live Attenuated Vaccinia and Other Poxviruses as Delivery Systems: Public Health Issues. <i>By</i> MARION E. PERKUS, JILL TAYLOR, JAMES TARTAGLIA, STEVEN PINCUS, ELIZABETH B. KAUFFMAN, JOHN A. TINE, and ENZO PAOLETTI | 222 |

Part V. Considerations for the Evaluation of Combination Vaccines: Clinical Design, Efficacy, and Statistical Issues

KAREN L. GOLDENTHAL and WALTER A. ORENSTEIN, *Co-chairs*

| | |
|--|-----|
| Issues in Design of Clinical Trials of Combination Vaccines. <i>By</i> MICHAEL D. DECKER and KATHRYN M. EDWARDS | 234 |
| Industry Perspective on Clinical Trial Issues for Combination Vaccines. <i>By</i> KENNETH R. BROWN | 241 |
| Practical Considerations Regarding the Impact on Immunization Schedules of the Introduction of New Combined Vaccines. <i>By</i> NEAL A. HALSEY | 250 |
| Interactions between PRP-T Vaccine against <i>Haemophilus influenzae</i> Type b and Conventional Infant Vaccines: Lessons for Future Studies of Simultaneous Immunization and Combined Vaccines. <i>By</i> JOHN CLEMENS, RUTH BRENNER, and MALLA RAO | 255 |
| International Prospects for Combined Vaccines with Emphasis on Quadrivalent Diphtheria-Tetanus-Pertussis-Hepatitis B Vaccine. <i>By</i> JOSEPH L. MELNICK | 267 |
| Defining Surrogate Serologic Tests with Respect to Predicting Protective Vaccine Efficacy: Pertussis Vaccination. <i>By</i> PATRICK OLIN | 273 |
| Laboratory Correlates of Protection against <i>Haemophilus influenzae</i> Type b Disease: Importance of Assessment of Antibody Avidity and Immunologic Memory. <i>By</i> DAN M. GRANOFF and ALEXANDER H. LUCAS | 278 |
| Defining Surrogate Serologic Tests with Respect to Predicting Protective Vaccine Efficacy: Poliovirus Vaccination. <i>By</i> ROLAND W. SUTTER, MARK A. PALLANSCH, LEIGH A. SAWYER, STEPHEN L. COCHI, and STEPHEN C. HADLER | 289 |
| Methodological Issues in the Evaluation and Monitoring of Vaccine Safety. <i>By</i> PAUL E. M. FINE | 300 |
| Surveillance of the Safety of Simultaneous Administration of Vaccines: The Centers for Disease Control and Prevention Experience. <i>By</i> ROBERT T. CHEN, PENINA HABER, and JOHN R. MULLEN | 309 |

| | |
|--|-----|
| Similarity/Equivalence Trials for Combination Vaccines. By WILLIAM C. BLACKWELDER | 321 |
| The Statistical Analysis of Immunogenicity Data in Vaccine Trials: A Review of Methodologies and Issues. By AMELIA DALE HORNE | 329 |

**Part VI. Clinical Considerations for the Evaluation
of Combination Vaccines**

KAREN L. GOLDENTHAL and WALTER A. ORENSTEIN, *Co-chairs*

| | |
|---|-----|
| Combination Live Enteric Virus Vaccines. By SAMUEL L. KATZ | 347 |
| Combination Live Respiratory Virus Vaccines. By MARY LOU CLEMENTS | 351 |
| Progress and Challenges for a New Combination Vaccine Composed of Diphtheria, Tetanus, Acellular Pertussis, and <i>Haemophilus b</i> Conjugate. By DACE V. MADORE | 356 |
| Surrogate Serologic Tests for the Prediction of Pertussis Vaccine Efficacy. By JAMES D. CHERRY, ULRICH HEININGER, PETER D. CHRISTENSON, THOMAS ECKHARDT, SUZANNE LAUSSUCQ, JILL G. HACKELL, JOSEPH R. MEZZATESTA, and KLEMENS STEHR | 359 |
| Comprehensive Evaluation of Vaccine Safety: Assessment of Local and Systemic Side Effects as well as Emergency and Hospital Utilization. By STEVEN BLACK and HENRY SHINEFIELD | 364 |
| Vaccine Licensure: A Proposal to Meet Changing Needs. By FREDERICK C. ROBBINS and EDWARD A. MORTIMER, JR. | 368 |
| Utility of Large-linked Databases in Vaccine Safety, Particularly in Distinguishing Independent and Synergistic Effects. By STEVEN G. F. WASSILAK, JOHN W. GLASSER, ROBERT T. CHEN, STEPHEN C. HADLER, and THE VACCINE SAFETY DATALINK INVESTIGATORS | 377 |
| Combination Vaccines: Some Practical Considerations. By ROBERT S. DAUM, ANJALI JAIN, and KAREN P. GOLDSTEIN | 383 |

Summary

| | |
|--|-----|
| Summary: A Perspective on Issues Relating to Future Vaccines. By BARRY R. BLOOM | 388 |
| Subject Index | 397 |
| Index of Contributors | 403 |